Using FDG PET/CT to Monitor Early Treatment Response in Glioblastoma Patients
Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
This study is testing if special scans can help doctors see how well chemotherapy is working for patients with glioblastoma just two days after starting treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT02902757 on ClinicalTrials.gov |
What this trial studies
This pilot clinical trial evaluates the use of fluordeoxyglucose (FDG) positron emission tomography (PET) and computed tomography (CT) to monitor very early therapy responses in patients diagnosed with glioblastoma. The study aims to assess changes in tumor glucose consumption within 48 hours of starting chemotherapy, which may indicate how well the treatment is working. Patients will undergo FDG PET/CT scans before and shortly after the initiation of therapy to correlate imaging results with clinical outcomes and survival rates.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed high-grade glioma who are planning to start chemotherapy.
Not a fit: Patients with severe psychiatric illnesses or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enable earlier identification of effective therapies for glioblastoma, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using imaging techniques to assess early treatment responses, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically proven high grade glioma * Intention to start therapy Exclusion Criteria: * Severe psychiatric illness * Inability to give written consent * Breast feeding / pregnancy
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Johannes Czernin, MD — UCLA / Jonsson Comprehensive Cancer Center
- Study coordinator: Soosan Roodbari
- Email: sroodbari@mednet.ucla.edu
- Phone: 310 794-1596
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.